![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
|Videos|January 25, 2017
Ibrutinib Yields Response in Patients With Chronic GVHD
Author(s)Lori Styles, MD
This video examines a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.
Advertisement
Chronic graft vs host disease (GVHD) is a serious complication of allogeneic stem cell transplantation, and among patients who fail corticosteroids there remains an unmet need for an effective therapy.
In this video, Lori Styles, MD, medical director of Pharmacyclics in Sunnyvale, California, discusses a phase I/II study of ibrutinib in patients with chronic GVHD who failed corticosteroids.
Results of the trial (
Advertisement
Related to this article
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.
Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5